Eldrug

Company Profile

Eldrug S.A. is a research Spin-off of High Technology company which was established in June of 2006 with an investment of €1.000.000 and a re-investment of another €1.000.000 from the Greek Pharmaceutical Company VIANEX owned by Paul, Constantine and Athanasios Giannakopoulos and a grant of €720.000 from the Greek Ministry of Development. The goal of ELDRUG is the Research and Development of Innovative Anti-hypertensive Products, including the most potent under the name of ELSARTAN. The spin-off with experience and know-how of its researchers in the Planning and Discovery of Pharmaceutical Products, possesses the rights of ELSARTAN and relative synthetic derivatives. Created by researchers including John Matsoukas, Professor of Chemistry at the University of Patras, Michael Maragoudakis, Emeritus Professor of Medicine at the University of Patras, Haralambos Gavras, Professor of Medicine at Boston University, Dimitrios Vlahakos, Associate Professor of Medicine at the University of Athens and younger researchers who are involved in the research project.

From January 2010, ELDRUG incorporated the assets of a highly innovative project, the “Elmyelin”, aimed at patients suffering from multiple sclerosis. These products are organic peptide compositions, similarly immuno dominant of the epitopes of Myelin protein which is involved in the pathology of multiple sclerosis and is the result of long research at the University of Patras.

Technologies / Services offered or sought

Organic Synthesis
Eldrug provides specific Medicinal Chemistry services for drug development process. Our Medicinal Chemists undertake synthesis of scaffolds and organic molecules (small scale, non GMP synthesis for research purposes).

Peptide Technology – Custom Peptides Synthesis
Eldrug’s Peptide chemists design and synthesize peptides in small and large scale. We synthesize high yield of linear and cyclic peptides by conventional or Microwave methods in solid phase.

Analytical services
In our laboratory, we offer chromatographic analyses (HPLC, UPLC-MS/MS) services specializing particularly in the analysis and identification of peptides and organic molecules.
• Physical and Chemical Characterization
• Stability studies
• Pharmacokinetics studies
• Method Development and Validation
• Consulting services in Drug Development.

Eldrug has been certified with ISO 9001:2008 quality management system from TUV. Our lab is focusing on improving methodologies in organic and solid phase peptide synthesis, making our priority the needs of our collaborators and customers.

Technology and R&D

Hypertension

One of the main goals of ELDRUG is the Research and Development of Innovative Anti-hypertensive Products, including the most potent under the name of ELSARTAN. The spin-off with experience and know-how of its researchers in the Planning and Discovery of Pharmaceutical Products possesses the rights of ELSARTAN and relative synthetic derivatives.

The company has already five substances-products in various stages of development and many other substances in the stage of basic research. The main strategic objective is the development of more "advanced" substances (ELSARTAN), and the evolution of other substances (ELUROSARTAN, ELAMINOSARTAN, ETRAP, ELGUARTAN, ELGONAD) as well as implementation research to identify new potential drug substances. ELDRUG is dealing also with the development of new formulations, antihypertensive  Molecules Dual Action suppression of Hypertension through receptor (Angiotensin System RAS, Renin Angiotensin System) and adrenoceptors (System SS, Sympathetic System), is based on the Histamine.

Hypertension Research Network

• Department of Chemistry, University of Patras, Greece
• Department of Medicine, University of Patras, Greece
• National Hellenic Research Foundation (NHRF) Athens, Greece
• Health Science Center, University of Calgary, Alberta, Canada
• Department of Pharmacology, Medical School, University of Crete, Greece
• Department of Chemistry, University of Athens, Greece
• Institute of Organic Chemistry and Biochemistry, Charles University of Prague, The Czech Republic
• Department of Internal Medicine, “Attikon” University Hospital, Athens, Greece

Multiple Sclerosis

ELDRUG is a Research and Development Company that deals with peptide and peptide mimetics synthesis, characterization and identification. Our Chemists are involved in the synthesis of linear and cyclic, MBP, PLP and MOG epitope analogues which are used as immunoregulator agents in Multiple Sclerosis research. Myelin epitopes MBP1-11, MBP74-85, MBP83-99, MOG35-55, MOG1-22, PLP139-151 are tools in drug discovery and development of new potent pharmaceuticals.

We can provide small to large-sequenced peptide analogues free of by-products identified and characterized in a lyophilized form for biological use only. For the synthesis of peptide analogues ELDRUG is equipped with high technology microwave peptide synthesizer (CEM Liberty).

Myelin Research Networking

• Department of Chemistry, University of Patras, Greece
• Department of Medicine, University of Patras, Greece
• Pasteur Institute, Athens, Greece
• Department of Medicine, Aristotle University of Thessaloniki, Greece
• Burnet-Austin Research Institute, Melbourne, Australia
• Department of Chemistry, University of Florence, Italy
• Department of Biochemistry, University of Tubingen, Germany
• Center for Molecular Medicine, Old Dominion, Virginia, U.S.A.
• Departments of Chemistry and Pharmacology, University of Cardiff, UK